MX2019003745A - Animales no humanos que tienen una expansion de repeticiones de hexanucleotidos en un locus c9orf72. - Google Patents

Animales no humanos que tienen una expansion de repeticiones de hexanucleotidos en un locus c9orf72.

Info

Publication number
MX2019003745A
MX2019003745A MX2019003745A MX2019003745A MX2019003745A MX 2019003745 A MX2019003745 A MX 2019003745A MX 2019003745 A MX2019003745 A MX 2019003745A MX 2019003745 A MX2019003745 A MX 2019003745A MX 2019003745 A MX2019003745 A MX 2019003745A
Authority
MX
Mexico
Prior art keywords
hexanucleotide repeat
repeat expansion
human animal
human animals
c9orf72 locus
Prior art date
Application number
MX2019003745A
Other languages
English (en)
Inventor
Macdonald Lynn
Frendewey David
Venus Lai Ka-Man
Droguett Gustavo
M Valenzuela David
Lacroix-Fralish Michael
Jen Siao Chia-
Guo Chunguang
Heslin David
ALLY Roxanne
Sharma Aarti
KAJIMURA Daisuke
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2019003745A publication Critical patent/MX2019003745A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Environmental Sciences (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona un modelo de animal no humano (por ejemplo, un roedor) para enfermedades asociadas con una secuencia heteróloga de expansión de repeticiones de hexanucleótidos en C9ORF72, cuyo animal no humano comprende una repetición heteróloga de hexanucleótidos (GGGGCC) en un locus C9ORF72 endógeno. Un animal no humano descrito en la presente descripción que comprende una secuencia heteróloga de expansión de repeticiones de hexanucleótidos que comprende al menos una instancia, por ejemplo, repetición, de una secuencia de hexanucleótidos (GGGGCC) puede exhibir además una característica y/o fenotipo asociado con uno o más trastornos neurodegenerativos (por ejemplo, esclerosis lateral amiotrófica (ALS) y/o demencia frontotemporal (FTD), etc.). También se proporcionan métodos para identificar candidatos terapéuticos que pueden usarse para prevenir, retrasar o tratar uno o más trastornos neurodegenerativos (por ejemplo, esclerosis lateral amiotrófica (ALS, también denominado enfermedad de Lou Gehrig) y demencia frontotemporal (FTD)).
MX2019003745A 2016-09-30 2017-09-29 Animales no humanos que tienen una expansion de repeticiones de hexanucleotidos en un locus c9orf72. MX2019003745A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662402613P 2016-09-30 2016-09-30
US201762452795P 2017-01-31 2017-01-31
PCT/US2017/054551 WO2018064600A1 (en) 2016-09-30 2017-09-29 Non-human animals having a hexanucleotide repeat expansion in a c9orf72 locus

Publications (1)

Publication Number Publication Date
MX2019003745A true MX2019003745A (es) 2019-12-11

Family

ID=60201654

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019003745A MX2019003745A (es) 2016-09-30 2017-09-29 Animales no humanos que tienen una expansion de repeticiones de hexanucleotidos en un locus c9orf72.
MX2021003996A MX2021003996A (es) 2016-09-30 2019-03-29 Animales no humanos que tienen una expansion de repeticiones de hexanucleotidos en un locus c9orf72.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021003996A MX2021003996A (es) 2016-09-30 2019-03-29 Animales no humanos que tienen una expansion de repeticiones de hexanucleotidos en un locus c9orf72.

Country Status (12)

Country Link
US (2) US10781453B2 (es)
EP (1) EP3518667A1 (es)
JP (2) JP7026678B2 (es)
KR (2) KR102527979B1 (es)
CN (1) CN109862785B (es)
AU (1) AU2017336100B2 (es)
CA (1) CA3038548A1 (es)
IL (2) IL265669B (es)
MX (2) MX2019003745A (es)
RU (1) RU2760877C2 (es)
SG (1) SG10202102997UA (es)
WO (1) WO2018064600A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6570447B2 (ja) 2012-10-15 2019-09-04 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｃ９ｏｒｆ７２発現を調節するための組成物
EP2906697A4 (en) 2012-10-15 2016-06-22 Ionis Pharmaceuticals Inc METHODS OF MONITORING C9ORF72 EXPRESSION
CN105637090B (zh) 2013-10-11 2020-10-16 Ionis制药公司 用于调节c9orf72表达的组合物
US10280418B2 (en) 2014-03-18 2019-05-07 Univeristy Of Massachusetts RAAV-based compositions and methods for treating amyotrophic lateral sclerosis
ES2784360T3 (es) 2015-05-29 2020-09-24 Regeneron Pharma Animales no humanos que tienen una interrupción en un locus C9ORF72
WO2017079291A1 (en) 2015-11-02 2017-05-11 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating c90rf72
WO2017109757A1 (en) * 2015-12-23 2017-06-29 Crispr Therapeutics Ag Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
MX2019003745A (es) * 2016-09-30 2019-12-11 Regeneron Pharma Animales no humanos que tienen una expansion de repeticiones de hexanucleotidos en un locus c9orf72.
EP3622073A4 (en) * 2017-05-09 2021-01-06 University of Massachusetts METHOD FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
EP3684937A4 (en) 2017-09-22 2021-06-02 University of Massachusetts DUAL EXPRESSION VECTORS OF SOD1 AND THEIR USES
CN113005123A (zh) * 2017-10-23 2021-06-22 普利维尔治疗公司 用于神经变性疾病的基因疗法
KR20210010549A (ko) * 2018-05-15 2021-01-27 유니버시티 오브 워싱톤 스플라이싱이상을 감소시키고 rna 우성 질환을 치료하기 위한 조성물 및 방법
MX2021007400A (es) * 2018-12-20 2021-07-15 Regeneron Pharma Expansion de repeticiones mediada por nucleasas.
EP3725536A1 (en) * 2019-04-18 2020-10-21 Thales Dis France SA Security document with double verification lenses
EP3966328A4 (en) 2019-05-06 2023-10-18 University Of Massachusetts ANTI-C9ORF72 OLIGONUCLEOTIDES AND RELATED METHODS
CN115151641A (zh) 2019-12-13 2022-10-04 阿尔尼拉姆医药品有限公司 人类染色体9开放阅读框72(C9ORF72)iRNA剂组合物及其使用方法
US20230040053A1 (en) * 2019-12-23 2023-02-09 Tsinghua University DEVELOPMENT OF DUAL-gRNA APPROACH WITH UNDETECTABLE OFF-TARGET EFFECT TO CORRECT C9ORF72 REPEAT EXPANSION AND C9ORF72 PATHOLOGY
US20230139408A1 (en) * 2020-04-09 2023-05-04 Association Institut De Myologie Antisense sequences for treating amyotrophic lateral sclerosis
WO2022086851A1 (en) * 2020-10-20 2022-04-28 The Scripps Research Institute Method for treating als/ftd through degradation of rna repeat expansion
JP2024521907A (ja) 2021-06-04 2024-06-04 アルナイラム ファーマシューティカルズ， インコーポレイテッド ヒト９番染色体オープンリーディングフレーム７２（Ｃ９ＯＲＦ７２）ｉＲＮＡ剤組成物及びその使用方法
AU2022379193A1 (en) * 2021-10-27 2024-04-11 University Of Florida Research Foundation, Incorporated Small molecule degradation methods for treating als/ftd
WO2024044493A2 (en) * 2022-08-22 2024-02-29 The Johns Hopkins University Treatment of repeat expansion disease

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514545A (en) * 1992-06-11 1996-05-07 Trustees Of The University Of Pennsylvania Method for characterizing single cells based on RNA amplification for diagnostics and therapeutics
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
AU8587598A (en) 1997-07-26 1999-02-16 Wisconsin Alumni Research Foundation Trans-species nuclear transfer
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
AUPR451401A0 (en) 2001-04-20 2001-05-24 Monash University A method of nuclear transfer
US7612250B2 (en) 2002-07-29 2009-11-03 Trustees Of Tufts College Nuclear transfer embryo formation method
PT2767161T (pt) 2004-10-19 2018-04-20 Regeneron Pharma Método para gerar um animal homozigótico para uma modificação genética
CN101117633B (zh) 2006-08-03 2011-07-20 上海交通大学附属儿童医院 一种细胞核移植方法
WO2009103027A2 (en) 2008-02-15 2009-08-20 Synthetic Genomics, Inc. Methods for in vitro joining and combinatorial assembly of nucleic acid molecules
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
US8518392B2 (en) 2009-08-14 2013-08-27 Regeneron Pharmaceuticals, Inc. Promoter-regulated differentiation-dependent self-deleting cassette
KR20120050485A (ko) * 2009-08-14 2012-05-18 레비비코르 인코포레이션 당뇨병 치료를 위한 복수 형질전환 돼지
EP3202914B2 (en) 2011-08-31 2023-06-28 The University of Manchester Method for treating a neurodegenerative disease
WO2013041577A1 (en) * 2011-09-20 2013-03-28 Vib Vzw Methods for the diagnosis of amyotrophic lateral sclerosis and frontotemporal lobar degeneration
US9834786B2 (en) 2012-04-25 2017-12-05 Regeneron Pharmaceuticals, Inc. Nuclease-mediated targeting with large targeting vectors
EP2906697A4 (en) 2012-10-15 2016-06-22 Ionis Pharmaceuticals Inc METHODS OF MONITORING C9ORF72 EXPRESSION
WO2014062686A1 (en) 2012-10-15 2014-04-24 Isis Pharmaceuticals, Inc. Methods for modulating c9orf72 expression
JP6570447B2 (ja) * 2012-10-15 2019-09-04 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｃ９ｏｒｆ７２発現を調節するための組成物
US8697359B1 (en) * 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014116865A1 (en) 2013-01-24 2014-07-31 Mayo Foundation For Medical Education And Research Methods and materials for detecting c9orf72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or c9orf72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis
SG11201505968WA (en) 2013-02-20 2015-08-28 Regeneron Pharma Genetic modification of rats
AU2014241078B2 (en) * 2013-03-14 2020-03-12 University Of Florida Research Foundation, Inc. Di-amino acid repeat-containing proteins associated with ALS
SG11201508028QA (en) * 2013-04-16 2015-10-29 Regeneron Pharma Targeted modification of rat genome
US10508289B2 (en) 2013-10-25 2019-12-17 Cellectis Rare-cutting endonucleases for efficient and specific targeting DNA sequences comprising highly repetitive motives
MX2016007325A (es) 2013-12-12 2017-07-19 Broad Inst Inc Composiciones y metodos de uso de sistemas crispr-cas en desordenes debidos a repeticion de nucleotidos.
US10280418B2 (en) * 2014-03-18 2019-05-07 Univeristy Of Massachusetts RAAV-based compositions and methods for treating amyotrophic lateral sclerosis
WO2015153760A2 (en) 2014-04-01 2015-10-08 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a nervous system disorder
SG10201803444YA (en) 2014-06-23 2018-06-28 Regeneron Pharma Nuclease-mediated dna assembly
RU2771532C2 (ru) 2014-06-26 2022-05-05 Регенерон Фармасьютикалз, Инк. Способы и композиции для нацеленных генетических модификаций и способы их применения
WO2016025692A1 (en) * 2014-08-13 2016-02-18 The Scripps Research Institute Treatment of c9ftd/als by targeting rna expanded repeat sequences
WO2016024205A1 (en) * 2014-08-15 2016-02-18 Pfizer Inc. Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
US10538762B2 (en) * 2014-10-14 2020-01-21 The Board Of Regents Of The University Of Texas System Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAS targeting the expanded hexanucleotide repeat
CN113444747A (zh) 2014-11-21 2021-09-28 瑞泽恩制药公司 使用成对向导rna进行靶向遗传修饰的方法和组合物
FI3850946T3 (fi) * 2014-12-05 2023-12-28 Regeneron Pharma Ei-ihmiseläimiä, joilla on humanisoitu erilaistumisklusterin 47 geeni
CN107208113A (zh) 2014-12-19 2017-09-26 瑞泽恩制药公司 用于通过单步多重靶向进行靶向遗传修饰的方法和组合物
WO2016112132A1 (en) 2015-01-06 2016-07-14 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
SG11201706809WA (en) * 2015-03-16 2017-09-28 Regeneron Pharma Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception
US11104897B2 (en) 2015-04-27 2021-08-31 Genethon Compositions and methods for the treatment of nucleotide repeat expansion disorders
US20180344817A1 (en) 2015-05-01 2018-12-06 Precision Biosciences, Inc. Precise deletion of chromosomal sequences in vivo and treatment of nucleotide repeat expansion disorders using engineered nucleases
ES2784360T3 (es) 2015-05-29 2020-09-24 Regeneron Pharma Animales no humanos que tienen una interrupción en un locus C9ORF72
US11390908B2 (en) 2015-09-02 2022-07-19 University Of Massachusetts Detection of gene loci with CRISPR arrayed repeats and/or polychromatic single guide ribonucleic acids
WO2017109757A1 (en) * 2015-12-23 2017-06-29 Crispr Therapeutics Ag Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
WO2017178590A1 (en) 2016-04-14 2017-10-19 Université de Lausanne Treatment and/or prevention of dna-triplet repeat diseases or disorders
WO2018022480A1 (en) 2016-07-25 2018-02-01 Mayo Foundation For Medical Education And Research Treating cancer
MX2019003745A (es) * 2016-09-30 2019-12-11 Regeneron Pharma Animales no humanos que tienen una expansion de repeticiones de hexanucleotidos en un locus c9orf72.
US20190256868A1 (en) 2016-10-28 2019-08-22 Genethon Compositions and methods for the treatment of myotonic dystrophy
US11427824B2 (en) 2016-10-28 2022-08-30 Genethon Compositions and methods for the treatment of myotonic dystrophy
WO2018165541A1 (en) 2017-03-10 2018-09-13 The Board Of Regents Of The University Of Texas System Treatment of fuchs' endothelial corneal dystrophy
EP3622073A4 (en) 2017-05-09 2021-01-06 University of Massachusetts METHOD FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
KR20200077529A (ko) 2017-10-24 2020-06-30 상가모 테라퓨틱스, 인코포레이티드 희귀 질환의 치료를 위한 방법 및 조성물

Also Published As

Publication number Publication date
RU2019108888A (ru) 2020-10-30
IL285014A (en) 2021-08-31
IL265669B (en) 2021-08-31
US20200370054A1 (en) 2020-11-26
KR102294755B1 (ko) 2021-08-31
SG10202102997UA (en) 2021-04-29
US20180094267A1 (en) 2018-04-05
KR102527979B1 (ko) 2023-04-28
US10781453B2 (en) 2020-09-22
JP2020198894A (ja) 2020-12-17
CA3038548A1 (en) 2018-04-05
IL265669A (en) 2019-05-30
EP3518667A1 (en) 2019-08-07
WO2018064600A1 (en) 2018-04-05
KR20190057104A (ko) 2019-05-27
JP7026678B2 (ja) 2022-02-28
RU2019108888A3 (es) 2021-01-18
JP2019530453A (ja) 2019-10-24
CN109862785A (zh) 2019-06-07
KR20210109649A (ko) 2021-09-06
MX2021003996A (es) 2021-06-23
AU2017336100A1 (en) 2019-05-23
RU2760877C2 (ru) 2021-12-01
AU2017336100B2 (en) 2023-11-30
CN109862785B (zh) 2022-09-06

Similar Documents

Publication Publication Date Title
MX2021003996A (es) Animales no humanos que tienen una expansion de repeticiones de hexanucleotidos en un locus c9orf72.
MX2017015369A (es) Animales no humanos que tienen una alteracion en un locus de c9orf72.
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
CL2019002535A1 (es) Composiciones para modular la expresión de sod-1.(divisional solicitud 201801897).
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
MX2020005477A (es) Inmunoterapias con el uso de células efectoras potenciadas derivadas de ipsc.
EP4269430A3 (en) Non-human animals having a humanized signal-regulatory protein gene
EA201790357A1 (ru) Способ получения клеток-предшественников зрелой печени
PH12016502170A1 (en) Humanized dipeptidyl peptidase iv (dpp4) animals
EA201690398A1 (ru) Способ получения клеток-предшественников зрелой печени
NZ761329A (en) Non-human animals comprising a humanized ttr locus and methods of use
MX2016012123A (es) Composiciones para modular la expresion de ataxina 2.
MX2021007400A (es) Expansion de repeticiones mediada por nucleasas.
JOP20200033A1 (ar) تركيبات حمض أميني لمعالجة مرض كبدي
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
WO2006053343A3 (en) Inflammation models in neurodegenerative and arthritic disorders
WO2008121199A3 (en) Transgenic animal models of disease
BR112018003741A2 (pt) composições biofarmacêuticas
SG11202011284RA (en) Non-human animal models of ditra disease and uses thereof
MX2019010219A (es) Modelo humanizado de trastornos renales y hepáticos.
CL2020000070A1 (es) Agentes, usos y métodos para el tratamiento.
MX2018005460A (es) Composicion de feromona para estimular reproduccion de hembras suids y metodos de uso.
MX2021002852A (es) Animal no humano que muestra una disminucion de la funcion de las motoneuronas superiores e inferiores y de la percepcion sensorial.
MX2019001211A (es) Ratones que comprenden mutaciones que dan lugar a la expresión de la fibrilina-1 truncada en c.
IL275767A (en) Compositions and methods for treating metabolic diseases